Announcements Trials
Browse Landscape

Phase

Phase 2 45Phase 1 12Phase 3 9Phase 1/2 7Phase NA 5Phase EARLY_PHASE1 3Phase 4 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Warts 1Recurrence 1Neutropenia 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia 1Infections 1Immunologic Deficiency Syndromes 1Hodgkin Disease 1Hematologic Neoplasms 1Febrile Neutropenia 1Congenital Abnormalities 1Breast Neoplasms 1Agammaglobulinemia 1

Interventions

Dexamethasone 8daratumumab 5Lenalidomide 5Bortezomib 5Thalidomide 4Cyclophosphamide 4carfilzomib 2Melphalan 2Calcium Dobesilate 2trametinib 1tanespimycin 1pomalidomide 1fludarabine 1dabrafenib 1cobimetinib 1Whole-Body Irradiation 1Vemurafenib 1Stem Cell Transplantation 1Rivaroxaban 1Mesna 1MAGEA3 protein, human 1Lenograstim 1Human Growth Hormone 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Busulfan 1Bone Marrow Transplantation 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Multiple Myeloma × Granulocyte Colony-Stimulating Factor × Clear all
NCT00177047 2021-11-09

Autologous Transplant for Multiple Myeloma

Masonic Cancer Center, University of Minnesota

Phase 2/3 Completed
363 enrolled 25 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡